Perspective Therapeutics (NYSEAMERICAN:CATX) Trading Down 7.2%

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) fell 7.2% during mid-day trading on Tuesday . The stock traded as low as 1.42 and last traded at 1.42. 4,018,949 shares traded hands during trading, an increase of 8% from the average session volume of 3,734,385 shares. The stock had previously closed at 1.53.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on CATX. B. Riley increased their target price on Perspective Therapeutics from $1.20 to $1.70 and gave the company a “buy” rating in a research report on Tuesday, April 9th. Oppenheimer reaffirmed an “outperform” rating and set a $1.50 target price (up previously from $1.20) on shares of Perspective Therapeutics in a research report on Monday, April 1st.

Perspective Therapeutics Trading Down 2.1 %

The company has a quick ratio of 1.07, a current ratio of 1.07 and a debt-to-equity ratio of 0.02.

Insider Transactions at Perspective Therapeutics

In other Perspective Therapeutics news, major shareholder Lantheus Alpha Therapy, Llc acquired 60,431,039 shares of the stock in a transaction dated Wednesday, March 6th. The stock was purchased at an average price of 0.95 per share, with a total value of 57,409,487.05. Following the transaction, the insider now directly owns 116,773,394 shares of the company’s stock, valued at 110,934,724.30. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, insider Markus Puhlmann bought 280,000 shares of Perspective Therapeutics stock in a transaction that occurred on Wednesday, January 24th. The stock was bought at an average price of 0.50 per share, for a total transaction of 140,000.00. Following the purchase, the insider now directly owns 1,375,425 shares of the company’s stock, valued at approximately 687,712.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Lantheus Alpha Therapy, Llc bought 60,431,039 shares of Perspective Therapeutics stock in a transaction that occurred on Wednesday, March 6th. The stock was purchased at an average price of 0.95 per share, with a total value of 57,409,487.05. Following the purchase, the insider now directly owns 116,773,394 shares in the company, valued at 110,934,724.30. The disclosure for this purchase can be found here. Insiders acquired 60,758,439 shares of company stock valued at $57,576,503 in the last quarter. 5.72% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Perspective Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its stake in shares of Perspective Therapeutics by 3.1% during the 4th quarter. Vanguard Group Inc. now owns 13,213,750 shares of the company’s stock valued at $5,312,000 after buying an additional 395,124 shares during the last quarter. Perkins Capital Management Inc. purchased a new position in shares of Perspective Therapeutics during the 3rd quarter valued at about $731,000. HighTower Advisors LLC purchased a new position in shares of Perspective Therapeutics during the 3rd quarter valued at about $314,000. Taylor & Morgan Wealth Management LLC raised its stake in shares of Perspective Therapeutics by 8.7% during the 4th quarter. Taylor & Morgan Wealth Management LLC now owns 625,000 shares of the company’s stock valued at $251,000 after buying an additional 50,000 shares during the last quarter. Finally, Bank of New York Mellon Corp purchased a new position in shares of Perspective Therapeutics during the 3rd quarter valued at about $42,000. Hedge funds and other institutional investors own 54.66% of the company’s stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.